An Open Label Randomized Comparative Clinical Study of Safoof-e-Mohazzil versus Atorvastatin in the Cases of Fart-e-Tadassum-Fid-Dam (Primary Hyperlipidaemia)
DOI:
https://doi.org/10.37591/rrjoush.v5i1.18Abstract
Hyperlipidaemia (Fart-e-Tadassum-Fid-Dam) is a common metabolic disease seen in clinical practice. It is mentioned that increased lipid level is associated with the pathogenesis of atherosclerosis. Theory of hyperlipidaemia meets similarly on the basis of etiology, presentation, complications, patho-physiology and non-pharmacological management with Saman-e-mufrit (obesity). Therefore, it is an important need to provide safe and effective drug from Unani system of medicine for the long term management of hyperlipidaemia. In the present study, all patients were randomly divided in two groups (test group and standard group). The patients of test groups received Safoof-e-Mohazzil 05 gm OD in morning and standard group received Atorvastatin (Atorva) 10 mg OD (HS). After intervention, most of the subjective parameters improved significantly in both interventional groups. While comparing to the test group vs. standard group, improvement of subjective parameters did not differ significantly. On objective parameters, improvement is very significant in both groups. All the biochemical parameters in each intervention groups had P=0.001. On comparison between test group vs. standard group by using unpaired “t” test, test drug is more effective than control drug for the increment on HDLc, lowering of BMI and WHR. The HDL cholesterols are considered as good cholesterols and help in lowering of BMI and WHR, so this is also beneficial effect of test drug.
Keywords: Safoof-e-Mohazzil, Fart-e-Tadassum-Fid-Dam, primary hyperlipidaemia
Cite this Article Md Razi Ahmed, Md Najibur Rahman, Jamal Akhtar et al. An Open Label Randomized Comparative Clinical Study of Safoof-e-Mohazzil versus Atorvastatin in the Cases of Fart-e-Tadassum-Fid-Dam (Primary Hyperlipidaemia). Research & Reviews: A Journal of Unani, Siddha and Homeopathy. 2018; 5(1): 6–12p.
Downloads
Published
Issue
Section
License
Declaration and Copyright Transfer Form
(to be completed by authors)
I/ We, the undersigned author(s) of the submitted manuscript, hereby declare, that the above manuscript which is submitted for publication in the STM Journals(s), is not published already in part or whole (except in the form of abstract) in any journal or magazine for private or public circulation, and, is not under consideration of publication elsewhere.
- I/We will not withdraw the manuscript after 1 week of submission as I have read the Author Guidelines and will adhere to the guidelines.
- I/We Author(s ) have niether given nor will give this manuscript elsewhere for publishing after submitting in STM Journal(s).
- I/ We have read the original version of the manuscript and am/ are responsible for the thought contents embodied in it. The work dealt in the manuscript is my/ our own, and my/ our individual contribution to this work is significant enough to qualify for authorship.
- I/We also agree to the authorship of the article in the following order:
Author’s name
1. ________________
2. ________________
3. ________________
4. ________________
| We Author(s) tick this box and would request you to consider it as our signature as we agree to the terms of this Copyright Notice, which will apply to this submission if and when it is published by this journal. |
